King's College London

Research portal

The ethical challenges of the clinical introduction of mitochondrial replacement techniques

Research output: Contribution to journalArticlepeer-review

Standard

The ethical challenges of the clinical introduction of mitochondrial replacement techniques. / Appleby, John B.

In: Medicine Health Care And Philosophy, Vol. 18, No. 4, 11.2015, p. 501-514.

Research output: Contribution to journalArticlepeer-review

Harvard

Appleby, JB 2015, 'The ethical challenges of the clinical introduction of mitochondrial replacement techniques', Medicine Health Care And Philosophy, vol. 18, no. 4, pp. 501-514. https://doi.org/10.1007/s11019-015-9656-3

APA

Appleby, J. B. (2015). The ethical challenges of the clinical introduction of mitochondrial replacement techniques. Medicine Health Care And Philosophy, 18(4), 501-514. https://doi.org/10.1007/s11019-015-9656-3

Vancouver

Appleby JB. The ethical challenges of the clinical introduction of mitochondrial replacement techniques. Medicine Health Care And Philosophy. 2015 Nov;18(4):501-514. https://doi.org/10.1007/s11019-015-9656-3

Author

Appleby, John B. / The ethical challenges of the clinical introduction of mitochondrial replacement techniques. In: Medicine Health Care And Philosophy. 2015 ; Vol. 18, No. 4. pp. 501-514.

Bibtex Download

@article{5c34d1ac35f8468db01cf8fe780acba5,
title = "The ethical challenges of the clinical introduction of mitochondrial replacement techniques",
abstract = "Mitochondrial DNA (mtDNA) diseases are a group of neuromuscular diseases that often cause suffering and premature death. New mitochondrial replacement techniques (MRTs) may offer women with mtDNA diseases the opportunity to have healthy offspring to whom they are genetically related. MRTs will likely be ready to license for clinical use in the near future and a discussion of the ethics of the clinical introduction of MRTs is needed. This paper begins by evaluating three concerns about the safety of MRTs for clinical use on humans: (1) Is it ethical to use MRTs if safe alternatives exist? (2) Would persons with three genetic contributors be at risk of suffering? and (3) Can society trust that MRTs will be made available for humans only once adequate safety testing has taken place, and that MRTs will only be licensed for clinical use in a way that minimises risks? It is then argued that the ethics debate about MRTs should be reoriented towards recommending ways to reduce the possible risks of MRT use on humans. Two recommendations are made: (1) licensed clinical access to MRTs should only be granted to prospective parents if they intend to tell their children about their MRT conception by adulthood; and (2) sex selection should be used in conjunction with the clinical use of MRTs, in order to reduce transgenerational health risks.",
author = "Appleby, {John B}",
year = "2015",
month = nov,
doi = "10.1007/s11019-015-9656-3",
language = "English",
volume = "18",
pages = "501--514",
journal = "Medicine Health Care And Philosophy",
issn = "1386-7423",
publisher = "Springer Netherlands",
number = "4",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - The ethical challenges of the clinical introduction of mitochondrial replacement techniques

AU - Appleby, John B

PY - 2015/11

Y1 - 2015/11

N2 - Mitochondrial DNA (mtDNA) diseases are a group of neuromuscular diseases that often cause suffering and premature death. New mitochondrial replacement techniques (MRTs) may offer women with mtDNA diseases the opportunity to have healthy offspring to whom they are genetically related. MRTs will likely be ready to license for clinical use in the near future and a discussion of the ethics of the clinical introduction of MRTs is needed. This paper begins by evaluating three concerns about the safety of MRTs for clinical use on humans: (1) Is it ethical to use MRTs if safe alternatives exist? (2) Would persons with three genetic contributors be at risk of suffering? and (3) Can society trust that MRTs will be made available for humans only once adequate safety testing has taken place, and that MRTs will only be licensed for clinical use in a way that minimises risks? It is then argued that the ethics debate about MRTs should be reoriented towards recommending ways to reduce the possible risks of MRT use on humans. Two recommendations are made: (1) licensed clinical access to MRTs should only be granted to prospective parents if they intend to tell their children about their MRT conception by adulthood; and (2) sex selection should be used in conjunction with the clinical use of MRTs, in order to reduce transgenerational health risks.

AB - Mitochondrial DNA (mtDNA) diseases are a group of neuromuscular diseases that often cause suffering and premature death. New mitochondrial replacement techniques (MRTs) may offer women with mtDNA diseases the opportunity to have healthy offspring to whom they are genetically related. MRTs will likely be ready to license for clinical use in the near future and a discussion of the ethics of the clinical introduction of MRTs is needed. This paper begins by evaluating three concerns about the safety of MRTs for clinical use on humans: (1) Is it ethical to use MRTs if safe alternatives exist? (2) Would persons with three genetic contributors be at risk of suffering? and (3) Can society trust that MRTs will be made available for humans only once adequate safety testing has taken place, and that MRTs will only be licensed for clinical use in a way that minimises risks? It is then argued that the ethics debate about MRTs should be reoriented towards recommending ways to reduce the possible risks of MRT use on humans. Two recommendations are made: (1) licensed clinical access to MRTs should only be granted to prospective parents if they intend to tell their children about their MRT conception by adulthood; and (2) sex selection should be used in conjunction with the clinical use of MRTs, in order to reduce transgenerational health risks.

U2 - 10.1007/s11019-015-9656-3

DO - 10.1007/s11019-015-9656-3

M3 - Article

VL - 18

SP - 501

EP - 514

JO - Medicine Health Care And Philosophy

JF - Medicine Health Care And Philosophy

SN - 1386-7423

IS - 4

ER -

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454